Purpose: Pulmonary hypertension (PH) associated with bronchopulmonary dysplasia presents a significant clinical challenge in premature infants, often complicated by concurrent patent ductus arteriosus (PDA). The absence of age-specific treatments complicates disease management and outcome optimization. This study aimed to evaluate the impact of PH and PDA on mortality in premature infants and assess treatment outcomes of various treatment modalities, including pharmacological and procedural interventions. Methods: This retrospective cohort study included 1,708 premature infants (born at <37 weeks of gestation) treated at Jeonbuk National University Children’s Hospital between January 2013 and August 2023. All infants included in the analysis underwent echocardiographic evaluation. Patients were grouped based on PH and PDA diagnoses, and clinical outcomes, such as mortality, were compared. Statistical analyses, including receiver operating characteristic curves and logistic regression, were conducted. Results: PH and PDA were diagnosed in 46 (2.7%) and 257 (15.0%) patients, respectively. Patients with PH had lower mean gestational ages and birth weights than those of patients with PDA. The mortality rates were 21.7% in patients with PH and 8.2% in those with moderate-to-large PDA. Multivariate analysis identified PH as a significant predictor of mortality. There were no significant differences in mortality between the PDA-treated and untreated groups. Although iloprost use was initially associated with increased mortality, this association was not statistically significant after adjusting for gestational age and birth weight Conclusion PH significantly impacts mortality in premature infants, highlighting the need for early diagnosis and tailored treatments. Continued research is pertinent for enhancing outcomes and the quality of care.

Purpose: Pulmonary hypertension (PH) associated with bronchopulmonary dysplasia presents a significant clinical challenge in premature infants, often complicated by concurrent patent ductus arteriosus (PDA). The absence of age-specific treatments complicates disease management and outcome optimization. This study aimed to evaluate the impact of PH and PDA on mortality in premature infants and assess treatment outcomes of various treatment modalities, including pharmacological and procedural interventions. Methods: This retrospective cohort study included 1,708 premature infants (born at <37 weeks of gestation) treated at Jeonbuk National University Children’s Hospital between January 2013 and August 2023. All infants included in the analysis underwent echocardiographic evaluation. Patients were grouped based on PH and PDA diagnoses, and clinical outcomes, such as mortality, were compared. Statistical analyses, including receiver operating characteristic curves and logistic regression, were conducted. Results: PH and PDA were diagnosed in 46 (2.7%) and 257 (15.0%) patients, respectively. Patients with PH had lower mean gestational ages and birth weights than those of patients with PDA. The mortality rates were 21.7% in patients with PH and 8.2% in those with moderate-to-large PDA. Multivariate analysis identified PH as a significant predictor of mortality. There were no significant differences in mortality between the PDA-treated and untreated groups. Although iloprost use was initially associated with increased mortality, this association was not statistically significant after adjusting for gestational age and birth weight Conclusion PH significantly impacts mortality in premature infants, highlighting the need for early diagnosis and tailored treatments. Continued research is pertinent for enhancing outcomes and the quality of care.

Purpose: Pulmonary hypertension (PH) associated with bronchopulmonary dysplasia presents a significant clinical challenge in premature infants, often complicated by concurrent patent ductus arteriosus (PDA). The absence of age-specific treatments complicates disease management and outcome optimization. This study aimed to evaluate the impact of PH and PDA on mortality in premature infants and assess treatment outcomes of various treatment modalities, including pharmacological and procedural interventions. Methods: This retrospective cohort study included 1,708 premature infants (born at <37 weeks of gestation) treated at Jeonbuk National University Children’s Hospital between January 2013 and August 2023. All infants included in the analysis underwent echocardiographic evaluation. Patients were grouped based on PH and PDA diagnoses, and clinical outcomes, such as mortality, were compared. Statistical analyses, including receiver operating characteristic curves and logistic regression, were conducted. Results: PH and PDA were diagnosed in 46 (2.7%) and 257 (15.0%) patients, respectively. Patients with PH had lower mean gestational ages and birth weights than those of patients with PDA. The mortality rates were 21.7% in patients with PH and 8.2% in those with moderate-to-large PDA. Multivariate analysis identified PH as a significant predictor of mortality. There were no significant differences in mortality between the PDA-treated and untreated groups. Although iloprost use was initially associated with increased mortality, this association was not statistically significant after adjusting for gestational age and birth weight Conclusion PH significantly impacts mortality in premature infants, highlighting the need for early diagnosis and tailored treatments. Continued research is pertinent for enhancing outcomes and the quality of care.

Purpose: Pulmonary hypertension (PH) associated with bronchopulmonary dysplasia presents a significant clinical challenge in premature infants, often complicated by concurrent patent ductus arteriosus (PDA). The absence of age-specific treatments complicates disease management and outcome optimization. This study aimed to evaluate the impact of PH and PDA on mortality in premature infants and assess treatment outcomes of various treatment modalities, including pharmacological and procedural interventions. Methods: This retrospective cohort study included 1,708 premature infants (born at <37 weeks of gestation) treated at Jeonbuk National University Children’s Hospital between January 2013 and August 2023. All infants included in the analysis underwent echocardiographic evaluation. Patients were grouped based on PH and PDA diagnoses, and clinical outcomes, such as mortality, were compared. Statistical analyses, including receiver operating characteristic curves and logistic regression, were conducted. Results: PH and PDA were diagnosed in 46 (2.7%) and 257 (15.0%) patients, respectively. Patients with PH had lower mean gestational ages and birth weights than those of patients with PDA. The mortality rates were 21.7% in patients with PH and 8.2% in those with moderate-to-large PDA. Multivariate analysis identified PH as a significant predictor of mortality. There were no significant differences in mortality between the PDA-treated and untreated groups. Although iloprost use was initially associated with increased mortality, this association was not statistically significant after adjusting for gestational age and birth weight Conclusion PH significantly impacts mortality in premature infants, highlighting the need for early diagnosis and tailored treatments. Continued research is pertinent for enhancing outcomes and the quality of care.

Purpose: Pulmonary hypertension (PH) associated with bronchopulmonary dysplasia presents a significant clinical challenge in premature infants, often complicated by concurrent patent ductus arteriosus (PDA). The absence of age-specific treatments complicates disease management and outcome optimization. This study aimed to evaluate the impact of PH and PDA on mortality in premature infants and assess treatment outcomes of various treatment modalities, including pharmacological and procedural interventions. Methods: This retrospective cohort study included 1,708 premature infants (born at <37 weeks of gestation) treated at Jeonbuk National University Children’s Hospital between January 2013 and August 2023. All infants included in the analysis underwent echocardiographic evaluation. Patients were grouped based on PH and PDA diagnoses, and clinical outcomes, such as mortality, were compared. Statistical analyses, including receiver operating characteristic curves and logistic regression, were conducted. Results: PH and PDA were diagnosed in 46 (2.7%) and 257 (15.0%) patients, respectively. Patients with PH had lower mean gestational ages and birth weights than those of patients with PDA. The mortality rates were 21.7% in patients with PH and 8.2% in those with moderate-to-large PDA. Multivariate analysis identified PH as a significant predictor of mortality. There were no significant differences in mortality between the PDA-treated and untreated groups. Although iloprost use was initially associated with increased mortality, this association was not statistically significant after adjusting for gestational age and birth weight Conclusion PH significantly impacts mortality in premature infants, highlighting the need for early diagnosis and tailored treatments. Continued research is pertinent for enhancing outcomes and the quality of care.

Background: The pediatric field in South Korea is experiencing a significant workforce crisis due to a sharp decline in pediatricians, exacerbated by a decrease in pediatric residents and a series of distressing incidents in pediatric healthcare institutions. No prior studies have explored the waning interest in pediatrics among South Korea’s medical students and interns, which our research seeks to address during a pediatric workforce decline. This study aimed to investigate the declining interest in pediatrics among medical students and interns in South Korea amidst decreasing birth rates. We conducted a comprehensive survey to identify the factors deterring young medical professionals from pursuing a career in pediatrics. Methods: In this cross-sectional study, in December 2023 we surveyed medical students and interns at Jeonbuk National University and Hospital using a 40-item electronically distributed questionnaire tailored to assess the factors influencing specialty choice, focusing on pediatrics. The participants were divided into the pre-clinical and clinical groups, allowing for analysis across educational stages. The survey covered demographics, perceptions of pediatrics, attitudes toward medical errors, and awareness of critical issues; it included a range of question types to ensure detailed and nuanced data collection. Results: Our findings revealed a clear decrease in interest in pediatrics as medical students progressed through their education, with 86.69% displaying negative views. Although a sense of mission and emotional satisfaction from patient interactions were highlighted as positive influences, they were significantly countered by worries related to declining pediatric populations, legal challenges, and interactions with patient guardians. Additionally, 95.84% of the participants recognized the critical role of vital pediatric departments; however, litigation risks and psychological burdens substantially affected their willingness to specialize in these areas. The analysis also showed an increasing awareness of pediatric incidents as students advanced through their education; however, this did not directly correlate with their choice of specialty (P = 0.090). Conclusion The results emphasize the necessity for targeted interventions to alleviate concerns and improve the attractiveness of pediatrics. These efforts are essential to counteract the declining interest and ensure a sustainable pediatric workforce for the future.

Multisystem inflammatory syndrome in children (MIS-C) is a rare complication of coronavirus disease 2019 (COVID-19), causing multi-organ damage affecting the heart, lungs, kidneys, digestive tract, and nervous system. As the cases of MIS-C have been increasing following the COVID-19 pandemic, the importance of appropriate management for MIS-C is becoming increasingly apparent. Immunomodulating agents such as anakinra, infliximab, and steroids are regarded as supplementary therapy to the first-line treatment with intravenous immunoglobulin. However, these immunomodulating therapies can potentially precipitate opportunistic infections, including those caused by cytomegalovirus (CMV), Epstein-Barr virus, and tuberculosis, or increase the risk of co-infections. Herein, we report a case of a 3-year-old boy who was treated with immunoglobulin, infliximab, and high-dose methylprednisolone for MIS-C, and subsequently developed a persistent fever lasting 32 days caused by a CMV infection.

Background: Kawasaki disease (KD) is the most common cause of acquired heart disease in paediatric patients, with infectious agents being the main cause. This study aimed to determine whether there are differences in the clinical manifestations of KD between patients with and without severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. Methods: From January 1, 2021 to August 15, 2022, 82 patients with analysable echocardiographic data were diagnosed with KD. Twelve patients with multisystem inflammatory syndrome in children were excluded. Serologic tests were performed by chemiluminescence immunoassay for both the nucleocapsid (N) and the spike (S) proteins in blood samples. Among the 70 patients diagnosed with KD at Jeonbuk University Children’s Hospital, the SARS-CoV-2 antibody test was performed in 41 patients. Results: The SARS-CoV-2 antibody test results for the N antigen were positive in 12 patients, while those for S protein were positive in 14 patients. N antigen SARS-CoV-2 antibodypositive KD was different from N antigen SARS-CoV-2 antibody-negative KD in terms of sex (male predominance in the positive group, 83.3% vs. female predominance in the negative group 62.1%, P = 0.008) and the incidence of refractory KD (41.7% vs. 10.3%, P = 0.034). The pro-B-type natriuretic peptide level was lower in the N-antigen SARS-CoV-2 antibody-positive KD group than that in the negative group (518.9 ± 382.6, 1,467.0 ± 2,417.6, P = 0.049). No significant differences in the echocardiographic findings between both groups were noted. In the multi-variable analysis, SARS-CoV-2 antibody (N antigen) was the only predictor of refractory KD (odds ratio, 13.70; 95% confidence interval, 1.63–115.44; P = 0.016). Conclusion High incidence of intravenous immunoglobulin-refractory KD may occur in up to 40% of the patients having recent history of coronavirus disease 2019. For patients having KD with N-type SARS-CoV-2 antibody positivity, adjunctive treatment, such as corticosteroids, can be considered as the first line of treatment.

Objective: To assess whether computed tomography (CT) conversion across different scan parameters and manufacturers using a routable generative adversarial network (RouteGAN) can improve the accuracy and variability in quantifying interstitial lung disease (ILD) using a deep learning-based automated software. Materials and Methods: This study included patients with ILD who underwent thin-section CT. Unmatched CT images obtained using scanners from four manufacturers (vendors A-D), standard- or low-radiation doses, and sharp or medium kernels were classified into groups 1–7 according to acquisition conditions. CT images in groups 2–7 were converted into the target CT sty le (Group 1: vendor A, standard dose, and sharp kernel) using a RouteGAN. ILD was quantified on original and converted CT images using a deep learning-based software (Aview, Coreline Soft). The accuracy of quantification was analyzed using the dice similarity coefficient (DSC) and pixel-wise overlap accuracy metrics against manual quantification by a radiologist. Five radiologists evaluated quantification accuracy using a 10-point visual scoring system. Results: Three hundred and fifty CT slices from 150 patients (mean age: 67.6 ± 10.7 years; 56 females) were included. The overlap accuracies for quantifying total abnormalities in groups 2–7 improved after CT conversion (original vs. converted: 0.63vs. 0.68 for DSC, 0.66 vs. 0.70 for pixel-wise recall, and 0.68 vs. 0.73 for pixel-wise precision; P < 0.002 for all). The DSCs of fibrosis score, honeycombing, and reticulation significantly increased after CT conversion (0.32 vs. 0.64, 0.19 vs. 0.47, and 0.23 vs. 0.54, P < 0.002 for all), whereas those of ground-glass opacity, consolidation, and emphysema did not change significantly or decreased slightly. The radiologists’ scores were significantly higher (P < 0.001) and less variable on converted CT. Conclusion CT conversion using a RouteGAN can improve the accuracy and variability of CT images obtained using different scan parameters and manufacturers in deep learning-based quantification of ILD.

Objective: To determine the usefulness of Silent MR angiography (MRA) for evaluating intracranial aneurysms treated with stent-assisted coil embolization. Materials and Methods: Ninety-nine patients (101 aneurysms) treated with stent-assisted coil embolization (Neuroform atlas, 71 cases; Enterprise, 17; LVIS Jr, 9; and Solitaire AB, 4 cases) underwent time-of-flight (TOF) MRA and Silent MRA in the same session using a 3T MRI system within 24 hours of embolization. Two radiologists independently interpreted both MRA images retrospectively and rated the image quality using a 5-point Likert scale. The image quality and diagnostic accuracy of the two modalities in the detection of aneurysm occlusion were further compared based on the stent design and the site of aneurysm. Results: The average image quality scores of the Silent MRA and TOF MRA were 4.38 ± 0.83 and 2.78 ± 1.04, respectively (p < 0.001), with an almost perfect interobserver agreement. Silent MRA had a significantly higher image quality score than TOF MRA at the distal internal carotid artery (n = 57, 4.25 ± 0.91 vs. 3.05 ± 1.16, p < 0.001), middle cerebral artery (n = 21, 4.57 ± 0.75 vs. 2.19 ± 0.68, p < 0.001), anterior cerebral artery (n = 13, 4.54 ± 0.66 vs. 2.46 ± 0.66, p < 0.001), and posterior circulation artery (n = 10, 4.50 ± 0.71 vs. 2.90 ± 0.74, p = 0.013). Silent MRA had superior image quality score to TOF MRA in the stented arteries when using Neuroform atlas (4.66 ± 0.53 vs. 3.21 ± 0.84, p < 0.001), Enterprise (3.29 ± 1.59 vs. 1.59 ± 0.51, p = 0.003), LVIS Jr (4.33 ± 1.89 vs. 1.89 ± 0.78, p = 0.033), and Solitaire AB stents (4.00 ± 2.25 vs. 2.25 ± 0.96, p = 0.356). The interpretation of the status of aneurysm occlusion exhibited significantly higher sensitivity with Silent MRA than with TOF MRA when using the Neuroform Atlas stent (96.4% vs. 14.3%, respectively, p < 0.001) and LVIS Jr stent (100% vs. 20%, respectively, p = 0.046). Conclusion Silent MRA can be useful to evaluate aneurysms treated with stent-assisted coil embolization, regardless of the aneurysm location and type of stent used.